Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review
暂无分享,去创建一个
[1] E. Delaporte,et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] C. Dye,et al. Global tuberculosis control: surveillance planning financing. WHO report 2003. , 2003 .
[3] T. Flanigan,et al. Lessons learned from use of highly active antiretroviral therapy in Africa. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[5] N. Ford,et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.
[6] L. Myer,et al. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. , 2006, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[7] Max Essex,et al. Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana , 2003, Journal of acquired immune deficiency syndromes.
[8] L. Myer,et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] I. Thior,et al. Initial Response to Highly Active Antiretroviral Therapy in HIV-1C-Infected Adults in a Public Sector Treatment Program in Botswana , 2005, Journal of acquired immune deficiency syndromes.
[10] D. Hamer,et al. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. , 2005, AIDS.
[11] L. Ivers,et al. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] D. Ngare,et al. Antiretroviral Durability and Tolerability in HIV-Infected Adults Living in Urban Kenya , 2007, Journal of acquired immune deficiency syndromes.
[13] S. De Geest,et al. Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.
[14] G. Harms,et al. Risk factors for treatment denial and loss to follow‐up in an antiretroviral treatment cohort in Kenya , 2007, Tropical medicine & international health : TM & IH.
[15] A. Hardon,et al. Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa , 2007, AIDS care.
[16] J. Sterne,et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.
[17] W. Miller,et al. Lessons Learned From a Paying Antiretroviral Therapy Service in the Public Health Sector at Kamuzu Central Hospital, Malawi , 2006, Journal of the International Association of Physicians in AIDS Care.
[18] T. F. Rinke de Wit,et al. Implementation of an Antiretroviral Access Program for HIV-1-Infected Individuals in Resource-Limited Settings: Clinical Results From 4 African Countries , 2007, Journal of acquired immune deficiency syndromes.
[19] Saad B Omer,et al. Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African Adults , 2006, Journal of acquired immune deficiency syndromes.
[20] P. Narciso,et al. One year of HAART in Mozambique: survival, virological and immunological results of DREAM project in Adults and Children , 2004 .
[21] A. Mocroft,et al. Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. , 1997, International journal of epidemiology.
[22] Anthony D Harries,et al. Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. , 2006, Bulletin of the World Health Organization.
[23] B. Marston,et al. A Program to Provide Antiretroviral Therapy to Residents of an Urban Slum in Nairobi, Kenya , 2007, Journal of the International Association of Physicians in AIDS Care.
[24] I. Buchan,et al. Adherence to HAART : A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators , 2006 .
[25] P. Weidle,et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.
[26] B. Chi,et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.
[27] G. Guyatt,et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. , 2006, JAMA.
[28] L. Myer,et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design , 2005, AIDS.
[29] S. Lawn,et al. How can earlier entry of patients into antiretroviral programs in low-income countries be promoted? , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] C. Mahé,et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? , 2002, AIDS.
[31] J. Saba,et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire , 2003, AIDS.
[32] N. Ford,et al. Scaling up HIV testing in resource-constrained settings: Debates on the role of VCT and Routine ‘Opt-in or Opt-out’ HIV Testing , 2005 .
[33] E. Delaporte,et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study , 2006, AIDS.
[34] B. Strom,et al. Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector , 2006, AIDS.
[35] P. Burkhart,et al. Adherence to long-term therapies: evidence for action. , 2003, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.
[36] L. Kumaranayake,et al. Evaluation of a workplace HIV treatment programme in South Africa , 2007, AIDS.
[37] Charles Kabugo,et al. Long-Term Experience Providing Antiretroviral Drugs in a Fee-for-Service HIV Clinic in Uganda: Evidence of Extended Virologic and CD4+ Cell Count Responses , 2005, Journal of acquired immune deficiency syndromes.
[38] Julio S. G. Montaner,et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.
[39] E. Schouten,et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. , 2007, Bulletin of the World Health Organization.
[40] Kara Wools-Kaloustian,et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya , 2006, AIDS.
[41] G. Maartens,et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.
[42] A. Harries,et al. Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.